Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 6
2008 1
2010 1
2020 2
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.
Miura A, Sootome H, Fujita N, Suzuki T, Fukushima H, Mizuarai S, Masuko N, Ito K, Hashimoto A, Uto Y, Sugimoto T, Takahashi H, Mitsuya M, Hirai H. Miura A, et al. Among authors: sootome h. Invest New Drugs. 2021 Jun;39(3):724-735. doi: 10.1007/s10637-020-01019-9. Epub 2021 Jan 6. Invest New Drugs. 2021. PMID: 33409897
A selective cellular screening assay for B-Raf and c-Raf kinases.
Ish T, Sootome H, Yagi Y, Yamashita K, Noumi T, Noro N, Ishii T. Ish T, et al. Among authors: sootome h. J Biomol Screen. 2007 Sep;12(6):818-27. doi: 10.1177/1087057107302308. Epub 2007 May 21. J Biomol Screen. 2007. PMID: 17517901